AMERICAN SOCIETY OF CLINICAL ONCOLOGY

FDA approves Kisqali (ribociclib) with aromatase inhibitor for HR+/HER2- stage II and III EBC at high risk of recurrence, based on NATALEE trial showing 25% reduced risk of recurrence vs. endocrine therapy alone, with consistent benefit across subgroups.

Diaceutics reports 24% revenue growth to £12.3m, with 55% of revenues recurring and a record order book of £27.9m. The company launched PMx, securing its first commercial contract, and is on track for profitability and cash flow generation from 2025.

Japan's MHLW accepts GSK's NDA for Blenrep plus BorDex or PomDex for relapsed/refractory multiple myeloma, based on DREAMM-7 and DREAMM-8 trials. Blenrep shows potential to redefine treatment landscape.

FDA approves Kisqali, a ribociclib-based treatment, in combination with an aromatase inhibitor for adjuvant therapy of HR+/HER2- stage II and III early breast cancer patients at high risk of recurrence, including those with node-negative disease. The approval is supported by the Phase III NATALEE trial results, which demonstrated a 25.1% reduction in disease recurrence risk and a well-tolerated safety profile.

Diaceutics reports 24% revenue growth, 28% on constant currency, with a record order book of £27.9m. 55% of revenues are recurring, aiming for 70% by 2025. The company added 26% more customer therapeutic brands and secured three new enterprise-wide engagements. PMx was launched, securing its first commercial contract. A two-year investment phase nears completion, with profitability and cash flow generation forecast from 2025. The balance sheet remains strong with £16.7m in cash.

Article references detail studies on cancer treatment, survivorship, quality of life, pain management, and integrative medicine, highlighting various aspects of cancer care and treatment outcomes.

Darolutamide plus androgen-deprivation therapy (ADT) significantly improved radiological progression-free survival (rPFS) by 46% versus placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC), with consistent benefits across subgroups and a favorable safety profile.

New therapy, ponsegromab, shows promise in treating cachexia, improving weight, appetite, and quality of life in cancer patients, according to a study published in The New England Journal of Medicine.

LeJeunesse, diagnosed with de novo metastatic breast cancer, advocates for cancer research through her podcast 'Cancer for Breakfast' and attends events like the Value in Cancer Care Summit. She is a clinical trials enthusiast and collaborates with her oncologist, Dr. Rachel Yung, who highlights the importance of patient involvement in research design. LeJeunesse also created the Breast Cancer Care-a-van, a mobile distribution center for cancer information and support.

The cell-free DNA isolation and extraction market is projected to grow from $1.81 billion in 2023 to $2.49 billion by 2028, driven by increasing cancer prevalence, advancements in genomics, and demand for personalized medicine. Key trends include product innovation, strategic partnerships, and technological advancements in DNA extraction techniques.